Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage

    Question

    Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage

    Direct answer

    Eli Lilly confirmed $27.7 billion in first-half 2026 sales across its incretin portfolio led by Mounjaro and Zepbound. Growth was augmented by broad pharmacy benefit manager (PBM) formulary inclusion for Foundayo, its oral obesity candidate. Newer therapies within the portfolio registered 121% year-over-year expansion in Q2, diversifying cash flows beyond injectable GLP-1 drugs while the stock consolidates after a 7% monthly pullback.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-glp-1-franchise-hits-27-7b-in-h1-2026-as-foundayo-gains-pbm-coverage-4b3588

    EQUITY
    Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage
    Eli Lilly confirmed $27.7 billion in first-half 2026 sales across its incretin portfolio led by Mounjaro and Zepbound. Growth was augmented by broad pharmacy benefit manager (PBM) formulary inclusion for Foundayo, its oral obesity candidate. Newer therapies within the portfolio registered 121% year-over-year expansion in Q2, diversifying cash flows beyond injectable GLP-1 drugs while the stock consolidates after a 7% monthly pullback.
    LLYNVO
    Impact
    65
    SEP 18
    SIG
    88%
    LLYNVO
    Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage
    Eli Lilly confirmed $27.7 billion in first-half 2026 sales across its incretin portfolio led by Mounjaro and Zepbound. Growth was augmented by broad pharmacy benefit manager (PBM) formulary inclusion for Foundayo, its oral obesity candidate. Newer therapies within the portfolio registered 121% year-over-year expansion in Q2, diversifying cash flows beyond injectable GLP-1 drugs while the stock consolidates after a 7% monthly pullback.
    → Broad PBM formulary placement for oral Foundayo expands market access, supporting double-digit revenue growth and offsetting GLP-1 manufacturing ramp costs for LLY.
    Impact
    Eli Lilly confirmed $27.7 billion in first-half 2026 sales across its incretin portfolio led by Mounjaro and Zepbound. Growth was augmented by broad pharmacy benefit manager (PBM) formulary inclusion for Foundayo, its oral obesity candidate. Newer therapies within the portfolio registered 121% year-over-year expansion in Q2, diversifying cash flows beyond injectable GLP-1 drugs while the stock consolidates after a 7% monthly pullback.
    Affected
    LLYNVO
    Transmission
    Broad PBM formulary placement for oral Foundayo expands market access, supporting double-digit revenue growth and offsetting GLP-1 manufacturing ramp costs for LLY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYoral GLP-1 volume adoption via PBM formulary accessUp1-3mGLP-1 franchise generated $27.7 billion in H1 2026 with Foundayo gaining major PBM coverage.
    NVOobesity market share competition across oral formulation classWatch1-4wPrimary competitor in the global incretin and obesity therapeutic category.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOWatch43.24 2026-09-18-7.96%-10.27%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month